SOCS1-KIR mimetic peptide

SOCS1-KIR mimetic peptide (also known as AT-002) is a synthetic 16-amino-acid peptide that mimics the kinase inhibitory region (KIR) of the endogenous suppressor of cytokine signaling 1 (SOCS1) protein. It acts as a potent inhibitor of the JAK/STAT pathway by binding to the activation loop of Janus kinase 2 (JAK2) and tyrosine kinase 2 (TYK2), thereby blocking downstream STAT1 activation and subsequent pro-inflammatory cytokine signaling. Originally developed in academic laboratories, including the University of Florida and the National Institutes of Health, the peptide is being developed by Arctic Therapeutics for the treatment of autoimmune uveitis, psoriasis, lupus, dermatomyositis, and cytokine storm syndromes.

Other names

R9-SOCS1-KIRR-9-SOCS1-KIRR 9-SOCS1-KIRSOCS1-KIRSOCS-1-KIRSOCS 1-KIRSOCS1-KIR peptideSOCS-1-KIR peptideSOCS 1-KIR peptidelipo-SOCS1-KIRlipo-SOCS-1-KIRlipo-SOCS 1-KIR